CN1048627C

CN1048627C - Medicaments

Info

Publication number: CN1048627C
Application number: CN93100477A
Authority: CN
Inventors: R·A·阿克赫斯特; A·J·泰勒; D·A·怀亚特
Original assignee: GLAXO
Current assignee: GLAXO; Glaxo Group Ltd
Priority date: 1992-02-06
Filing date: 1993-01-02
Publication date: 2000-01-26
Anticipated expiration: 2013-01-02
Also published as: GB9202522D0; CN1063321C; CN1075079A; CN1152669C; CN1284330A; CN1075078A

Abstract

This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant and up to 5 % w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

Description

Medicinal aerosol formulations

The present invention relates to the aerosol preparations that the confession inhalation is used.

People have just known with the aerosol administration before the many decades.Aerosol comprises medicine, one or more Chlorofluorocarbons (CFCs) propellant and surfactant or solvent, for example ethanol usually.The most frequently used aerosol propellant is 11 (CCl always in the medicine ₃F) and/or propellant 114 (CF ₂ClCF ₂Cl) with propellant 12 (CCl ₂F ₂).But it is believed that now these propellant can cause the decomposition of stratospheric ozone, thereby the medicinal aerosol formulations of the propellant that uses so-called " to the ozone friendliness " need be provided.

It is believed that a class propellant compares with the fluorochlorohydrocarbon of routine and have minimum ozone dilution effect (Ozone-depleting effects), this propellant comprises fluorocarbon and hydrogeneous fluorochlorohydrocarbon, adopt the multiple medications aerosol preparations of this propellant to be disclosed in for example EP0372777, WO091/04011, WO91/11173, WO91/11495 and WO91/14422.Above-mentioned application all is the preparation about the administrable pressurized aerosol, and tries hard to overcome the problem relevant with the use of new class propellant, specifically overcomes and the relevant problem of pharmaceutical formulation stability that makes.Above-mentioned application all proposes to add a small amount of one or more adjuvant even conventional Chlorofluorocarbons (CFCs) propellant, so that the potential destruction of ozone is reached minimum.Described examples of auxiliaries has: alcohols, alkane, dimethyl ether, surfactant (comprise and fluoridizing or surfactant, carboxylic acid, many b-oxides of nonfluorinated).

Thereby for example EP0372777 requires 1,1,1, the 2-tetrafluoroethane with have than 1,1,1, cosolvent of 2-tetrafluoroethane high polarity (for example: alcohol or lower paraffin hydrocarbon) and surfactant use together, to obtain stable medicated powder preparation.It is pointed out particularly at page 3 the 7th row: " having found that; use the binary mixture of propellant 134a (1; 1; 1, the 2-tetrafluoroethane) and medicine or unite use with conventional surfactants (for example sorbitan trioleate) to obtain the preparation that sacrificial vessel has the character that the inhaler that is fit to pressurize uses ".Those skilled in the art it is generally acknowledged: surfactant is the important component of aerosol preparations, not only needs it to reduce the coalescent of medicine but also needs it to lubricate used valve, thereby guarantee the constant repeatability of valve event and the accuracy of dosage.WO91/11173, WO91/11495 and WO91/14422 are about comprising the preparation of medicine and surfactant mixture, and WO91/04011 then discloses a kind of pharmaceutical aerosol preparation, granulated drug wherein is with 1,1,1, the 2-tetrafluoroethane is handled before just in advance coated with surfactant.

We find now uncannily, opposite with above-mentioned situation, in fact needn't lean against in the composition use surfactant or must be before handling with propellant pretreatment (for example: 1,1 just can access medicine at fluorocarbon or hydrochlorofluorocarsolvent propellant, 1,2-tetrafluoroethane) the satisfied dispersion in.

Therefore, one aspect of the present invention provides a kind of medicinal aerosol formulations, and it comprises granulated drug, fluorocarbon or hydrochlorofluorocarsolvent propellant and is no more than the polar co-solvent of 5 weight % (is benchmark with the propellant), and said preparation is substantially free of surfactant.So-called " being substantially free of surfactant " is meant the preparation of the surfactant that does not contain obvious amount, and for example content is less than 0.0001 weight % of medicine.

The particle diameter of granular (for example micronized) medicine should allow basically all medicines to suck in lungs when taking this aerosol preparations, therefore, should be less than 100 microns, with less than 20 microns for well, the 1-10 micron is best, for example: the 1-5 micron.

Medicine that can the aerosol preparations form administration of the present invention comprises any medicine that can be used for sucking treatment, and the form that it can be insoluble to selected propellant basically exists.Therefore, suitable medicine can be selected from, analgesic for example, for example: codeine, paramorphane, Ergotamine, fentanyl or morphine; The persantin preparation, for example: sulfur nitrogen ketone; Anti-allergic drug, for example: cromoglycate, ketotifen or anti-many grammeters (nedocromil); Anti-infective, cephalosporin for example, penicillin, streptomycin, sulfonamides, tetracycline and pentamidine; Antihistaminic, for example, sleepwell; The antibiotic medicine, for example, beclomethasone, 9-remove fluorine fluocinonide, budesonide, general dawn of the base of a fruit (tipredane), the third scorching pine or fluticasone (fluticasone); Cough medicine, for example: oscapine; Bronchodilator, for example: ephedrine, epinephrine, fenoterol, formoterol (formoterol), isoprenaline, alotec, phenylephrine, phenylpropanolamine, pyrrole butanols, D-1959, asmaten, salbutamol, salmaterol (salmeterol), terbutaline, Dilabron, C-78, hydroxyl is breathed heavily or (-)-4-amino-3,5-two chloro-α-[[[6-[2-(2-pyridine radicals) ethyoxyl] hexyl] amino] methyl] benzyl alcohol; Diuretic, for example: amiloride; Anticholinergic agent, for example, Ipratropium Bromured, atropine or second scopolamine; Hormone, for example: cortisone, hydrocortisone or meticortelone; Xanthine, for example, aminophylline, Oxtriphylline, theophylline-lysine or theophylline and treatment protein and peptide, for example: insulin or glucagon.To those skilled in the art, obviously, in the time of suitably said medicine can with salt (for example: alkali metal salt or amine salt or acid-addition salts) or ester (for example: lower alkyl esters) or solvate (for example: form hydrate) is used, so that the active and/or stability of medicine reaches best and/or make the dissolubility of medicine in propellant reach minimum.

Comprise by sucking used anti-allergic drug, bronchodilator and anti-inflammatory type sterol compound in the therapy treatment respiratory disorder (for example asthma), for example with the preferred medicine of aerosol preparations administration of the present invention: cromoglycate (for example sodium salt), salbutamol (for example: the form of free alkali or sulfate), salmaterol (for example: the form of Hydroxynaphthoate), terbutaline (for example: sulphate form), D-1959 (for example: hydrochloride form), Beclomethasone.FLUTICASONE PROPIONATE or (-)-4-amino-3,5-dihydro-α-[[[6-[2-(2-pyridine radicals)-ethyoxyl] hexyl] amino] methyl] benzyl alcohol.Salmaterol, uncle's fourth breathe heavily that, FLUTICASONE PROPIONATE, Beclomethasone and physiologically acceptable salt thereof and solvate preferred especially.

This area professional is apparent, and aerosol preparations of the present invention in case of necessity can comprise the combination of two or more active component.For example, the aerosol composition that contains two kinds of active component (in conventional propellant system) has been used to the treatment of respiratory disorder (for example asthma).Therefore, the present invention further provides the aerosol preparations of the present invention that contains two or more granulated drug.Medicine can be selected from the appropriate combination of said medicine.Thereby the appropriate combination of bronchodilator comprises that ephedrine and the thiophene film (thiophylline), fragrant third breathe heavily peace Ipratropium Bromured, Dilabron and phenylephrine aerosol preparations.

The preferred aerosol preparations of the present invention comprises (a) effective amount of particulate bronchodilator, (b) effective amount of particulate antibiotic medicine, preferably steroid antibiotic medicine, (c) fluorocarbon or hydrochlorofluorocarsolvent propellant, (d) be no more than the cosolvent of 5% (W/W is a benchmark in the propellant).Particularly preferred aerosol preparations contains bronchodilator, salbutamol (for example: free alkali or sulphate form), Sha Ermaite (for example hydroxynaphthoic acid salt form or isoprenaline for example, be mixed with the anti-inflammatory type sterin simultaneously, as beclomethasone ester (for example dipropionate) or fluorine Kazon ester (for example propionic ester).Perhaps, aerosol preparations can comprise bronchodilator and anti-allergic drug, as cromoglycate (for example: sodium salt).Isoprenaline and sodium cromoglicate; Sha Ermaite and propionate propionate fluoride; Or salbutamol, Beclomethasone is preferred especially.

Final aerosol preparations preferably contains 0.005-10%, and 0.005-5%W/W is better, particularly the medicine of 0.01-1.0%W/W (with respect to the gross weight of preparation).

The used propellant of the present invention can be any fluorocarbon or hydrochlorofluorocarsolvent or its mixture, and they should have enough vapour pressures so that as effective propellant.Propellant is the non-solvent of medicine preferably.For example: suitable propellant comprises: the hydrochlorofluorocarsolvent of C1-4, for example CH ₂ClF, CClF ₂CHClF, CF ₃CHClF, CHF ₂CClF ₂, CHClFCHF ₂, CF ₃CH ₂Cl and CClF ₂CH ₃, the hydrogen-containing carbon fluorine compounds of C1-4, for example CHF ₂CHF ₂, CF ₃CH ₂F, CHF ₂CH ₃And CF ₃CHFCF ₃With perfluorocarbon CF for example ₃CF ₃And CF ₃CF ₂CF ₃

When using the mixture of fluorocarbon or hydrochlorofluorocarsolvent, they can be above-claimed cpd or mixture (preferably binary mixture) and other fluorocarbon or hydrochlorofluorocarsolvent (CHClF for example ₂, CH ₂F ₂And CF ₃CH ₃) mixture.Preferably adopt single fluorocarbon or hydrochlorofluorocarsolvent as propellant.Preferred especially is C as propellant _1-9The hydrogen-containing carbon fluorine compounds, for example 1,1,1,2-tetrafluoroethane (CF ₃CH ₂F) and 1,1,1,2,3,3,3-seven fluorine n-propane (CF ₃CHFCF ₃).

Preparation of the present invention does not preferably contain the component that can cause that stratospheric ozone decomposes.Especially preferably do not contain substantially in the preparation such as CCl ₃F, CCl ₂F ₂And CF ₃CCl ₃And so on Chlorofluorocarbons (CFCs).

Propellant also can contain the volatility adjuvant, for example saturated hydrocarbons propane, normal butane, pentane and isopentane or dialkyl ether dimethyl ether for example for example.Usually, the propellant that is no more than 50%W/W can comprise for example volatile hydrocarbon of 1-30%W/W.But the preparation that is substantially free of the volatility adjuvant is preferred.

The polar co-solvent that can sneak into preparation of the present invention (for example: C comprises _2-6) aliphatic alcohol and polyhydric alcohol, for example ethanol, isopropyl alcohol and propylene glycol and composition thereof.Preferably use ethanol.Usually only need a small amount of (for example 0.05-3.0%W/W) polar co-solvent to promote to disperse, when consumption surpasses 5%W/W, may cause being unfavorable for the dissolving of medicine.Preparation preferably contains and is less than 1%W/W, for example the polar co-solvent of about 0.1%W/W.Polar mensuration can disclose the 0327777th described method by for example european patent application and carry out.

Particularly preferred embodiment of the present invention provides a kind of medicinal aerosol formulations, and it mainly comprises the polar co-solvent of one or more granulated drug, one or more fluorocarbons or hydrochlorofluorocarsolvent propellant and 0.01-5%W/W (is benchmark with the propellant).

In proper container, for example,, medicine is scattered in the selected propellant can makes preparation of the present invention by means of sonication.

May be preferably with medicine with adding cosolvent again after propellant mixes, because can make any solvation effect of cosolvent reach minimum like this, thereby has strengthened dispersion.This process is preferably under the anhydrous condition carries out, in order to avoid dampness is to any adverse effect of suspension stability.

Form flocculating suspension slightly after preparation of the present invention leaves standstill, amazing is that even find through long-term storage, suspension obtains being applicable to that through slowly stirring very easily redispersion the pressurization inhaler has fabulous suspension for property of medicine energy.Make formulation excipients in the aerosol preparations of the present invention (for example surfactant) minimum, preferably need not, also be favourable, because the tasteless basically nothing of preparation is smelt, than less zest of conventional formulation and toxicity.

The technology that the pharmacy of aerosol preparations of the present invention mensuration acceptable and physics and chemical stability can adopt this area professional to know is carried out.Therefore, for example, the chemical stability of each component can be passed through the HPLC assay determination at for example product after long-term storage.The physical stability data can obtain by other conventional analysis technology, for example, by leak test, by valve for medicine evaluation (each open the average weight that penetrates), by dosage repeatability evaluation (each active principle that penetrates of opening) with spray the medicine distributional analysis.

The particle size distribution of aerosol preparations of the present invention is given deep especially seal and is thought, can measure by routine techniques, for example: measure by collision (cascade impaction) or " binary collision " (Twin Impinger) analytical method step by step.Alleged herein " binary collision " calibrating is meant " deposition of measuring the ejection medicament with device A in adding the pressure solution device ", and British Pharmacopoeia 1988, the A204-207 pages or leaves are seen in this definition, symbol record XVIIC.This technology can calculate " can breathe part " of aerosol preparations.Alleged herein " can breathe part " is meant the method that adopts above-mentioned " binary collision ", opens the amount of the active component of collecting from the collision cell bottom at every turn, is expressed as the percent of the active component total amount of each unlatching ejection.We find that but the respiratory region of preparation of the present invention is divided into drug weight 20% or higher, preferably 25-70%, for example 30-60%.

Medicine also can carry out surface modification before disperseing with propellant, that is, and and with the non-solvent of medicine, nonpolar liquid medium processing basically.Thereby, the present invention further provides a kind of aerosol preparations, it comprises granulated drug, fluorocarbon or the hydrochlorofluorocarsolvent propellant of surface modification as defined above and is no more than the polar co-solvent of propellant 5%W/W, and said preparation is substantially free of surfactant.So-called " medicine of surface modification " be meant and nonpolar non-solvent liquid mixing basically, removes liquid again and by the drug particles of surface modification.(for example: lower paraffin hydrocarbon) be advisable, after medicine slurrying, it has enough volatility to this nonpolar basically non-solvent liquid medium under for example room temperature and normal pressure with it, very easily evaporation with aliphatic hydrocarbon.In this respect, adopt different propane as the liquid medium advantageous particularly.

Be preferably under the anhydrous condition medicine with liquid medium slurrying, in order to avoid dampness has a negative impact to suspension stability.Serosity is preferably through acoustical treatment, to reach the best surface modified effect.Can adopt any method easily to remove liquid, for example evaporation or filtration, evaporation supposes that subsequent treatment is anhydrous basically subsequently.Preparation of the present invention is substantially free of the non-solvent nonpolar liquid.

Preparation of the present invention can be packed into and is suitable for emitting in the tube of medicinal aerosol formulations.Described tube generally includes a container that can bear used propellant vapour pressure, plastics or the vial that is coated with plastics canister preferably for example, aluminium pot for example, it can be apply through anodization, varnish and/or plastic coat, this container seals with a metering valve.The metering valve amount is used for providing the preparation of metered amount when each the unlatching, and a liner is housed leaks from valve to prevent propellant.Liner can comprise any suitable elastic material, for example: low density polyethylene (LDPE), chlorobutyl, black or white acrylonitrile-butadiene rubber, butyl rubber and neoprene.Suitable valve can be buied from the manufacturer that aerosol industry is known, for example from Valois, France (DF10 for example, DF30, DF60), Bespakplc, Britain (BK300 for example, BK356) and 3M-NeotechnicLtd, Britain (Spraymiser for example ^TM) buy.

The conventional batch manufacturing method and the equipment that can use medical aerosol manufacturing field professional to know carry out the large-scale production of fitted tube medicine.Therefore, for example, in a kind of batch manufacturing method, metering valve is crimped on the empty tube of formation on the aluminium pot.Granulated drug is packed in the filling containers, and the propellant of polar solvent and liquefaction charged into by the filling containers pressurization make in the container.Before entering the filling machine circulation, drug suspension is mixed, aliquot drug suspension is charged in the tube by metering valve.Perhaps, when medicine is soluble in polar co-solvent, can before adding cosolvent, granulated drug be suspended in the propellant of 50-90%W/W, before pressurization charges in the tube, mix then and weigh with propellant.Usually in the producing by batch of medicine, with the tube check of each filling, weigh, stamp lot number, deposit in the dish of before release test, packing into.

Each tube of filling can make it to be suitable for a suitable channel unit before use, forming metered dose inhaler, so that to patient's lung or nasal-cavity administration.Suitable channel unit comprises for example opening of valves device and column or conial channel, and medicine can be sent in patient's the nose or mouth, for example by metering valve by the tube of filling through this passage: the ozzle actuator.Metered dose inhaler is used for providing fixed unit dose when each unlatching or injection, for example: spray 10-5000 μ g medicine at every turn.

Administration is suitable for treating gentle, moderate or serious acute or chronic sympton, or prophylactic treatment.Self-evident, accurate dosage will depend on the patient's age and the state of an illness, employed concrete granulated drug and administration frequency, and finally determine by the clinicist.During drug combination, the dosage the when dosage of each component is generally its independent medication.In general, can be administered once every day or repeatedly, for example 1-9 time, spray medicine for example 1,2,3 or 4 times at every turn.

Thereby, for example, drive valve at every turn 25 μ g salmaterol can be provided, 100 μ g salbutamols, 25,50,125 or 50 μ g FLUTICASONE PROPIONATE or 50,100,200 or 250 μ g Beclomethasones.Each used filling tube comprises the medicine of 100,160 or 240 dosings or injecting times in the general metered dose inhaler.

The tube and the metered dose inhaler of filling as herein described have constituted another aspect of the present invention.

The method that comprises on the one hand treatment respiratory disorder (for example asthma) more of the present invention, it comprises and sucks the preparation as herein described of taking effective dose.

Following non-limiting example is used for illustrating the present invention.

Embodiment 1

(9.57mg) directly weighs in the opening aluminium pot with micronized Salmeterolxinafoate.With 1,1,1,2-tetrafluoroethane (18.2g) adds from vacuum flask with ethanol (182mg), and the metering valve crimping is good.The gained aerosol contains 9.57mg Salmeterolxinafoate (1.0%W/W ethanol), each ejection 25 μ g Sha Ermaite that open.

Embodiment 2

(9.57mg) directly weighs in the opening aluminium pot with micronized Salmeterolxinafoate.With 1,1,1,2-tetrafluoroethane (182mg) adds from vacuum flask with ethanol (455mg), and the metering valve crimping is good.Contain 9.57mg Salmeterolxinafoate (2.5% W/W ethanol) in the gained inhaler, each ejection 50 μ g salmaterol of opening.

Embodiment 3 and 4

(66mg or 6.6mg) directly weighs in 100 opening aluminium pots separately with micronized FLUTICASONE PROPIONATE, then metering valve is crimped on each jar.Add and depress, in each, add ethanol (0.182g) and 1,1,1 by valve, 2-tetrafluoroethane (18.2g), with the tube vibration of each filling with dispersion medicine.Contain 66 or 6.6mg FLUTICASONE PROPIONATE (1%W/W ethanol) in the gained insufflator, each ejection 250 or 25 μ g FLUTICASONE PROPIONATE (corresponding respectively to embodiment 3 and 4) of opening.

Embodiment 5 and 6

(24mg or 48mg) directly weighs respectively in three opening aluminium pots with micronized salbutamol.With 1,1,12-sym-tetrachloroethane (18.2g) adds each jar from vacuum flask with ethanol (0.364g), and the metering valve crimping is good.Tube with each filling vibrated 8 minutes in ultrasonic bath then.Contain 24mg or 48mg salbutamol (2% W/W ethanol) in the gained inhaler, each ejection 100 or 200 μ g salbutamols (corresponding respectively to embodiment 5 and 6) of opening.

Embodiment 7

Micronized salbutamol sulfate (15mg) is directly weighed in the opening aluminium pot.With 1,1,1,2 one tetrafluoroethane (18.2g) and ethanol (0.182g) add from vacuum flask together, and the metering valve crimping is good.The tube that to fill then vibrated 5 minutes in ultrasound wave is molten.Contain 15mg salbutamol sulfate (1% W/W ethanol) in the gained inhaler.

Embodiment 8

Isopentane (20ml) is added in the micronized Salmeterolxinafoate (0.5g), forms serosity, sonication 3 minutes.The gained suspension is evaporated isopentane to dry in room temperature, get the Salmeterolxinafoate of surface modification.Pack into after this product sample (9.57mg) weighed in the aerosol can, add 1,1,1,2-tetrafluoroethane (18.2g-99.95%W/W, total loading is a benchmark), the suitable metering valve of crimping on jar.The tube of filling is distinguished sonication 5 minutes.Salmaterol content is equivalent to spray 25 μ g at every turn in the gained aerosol, can spray 240 times amount (0.5%W/W ethanol).

Embodiment 9

Pack into after a micronized hydration Beclomethasone (68mg) weighed in the vial of drying, cleaning, plastic coat, add 1,1,1 from vacuum flask, 2-tetrafluoroethane and ethanol (≤0.182g), rapidly bottle is sealed with metering valve.The gained aerosol dispersion has 250mg Beclomethasone (as monohydrate), each ejection 75.8 μ g (1%W/W ethanol) that open.

Embodiment 10

(1.2g) directly weighs in aluminium pot with micronized sodium cromoglicate, with 1,1,1, the 2-tetrafluoroethane (≤18.2g) add from vacuum flask with ethanol (455mg).The crimping metering valve was with the tube sonication of filling 5 minutes.This aerosol is opened ejection 5 μ g sodium cromoglicate (2.5%W/W ethanol) at every turn

Embodiment 11

Micronized uncle's fourth is breathed heavily your sulfate (60mg) in aluminium pot, directly weighs, add 1,1,1 from Dewar bottle, the 2-tetrafluoroethane (≤18.2g) with ethanol (91mg).The metering valve crimping is good, with the tube sonication of filling 5 minutes.The each unlatching of this aerosol provides 250 μ g terbutaline sulfate (0.5W/W ethanol).

Embodiment 12

(120mg) directly weighs in aluminium pot with micronized W-2946M, with 1,1,1, the 2-tetrafluoroethane (≤18.2g) add from vacuum flask with ethanol (364mg).The crimping metering valve was with the tube sonication of filling 5 minutes.This aerosol is opened ejection 500 μ g W-2946Ms (2%W/W ethanol) at every turn

Embodiment 13

Micronized terbutaline sulfate (60mg) is directly weighed in aluminium pot, adds 1,1,1,2,3,3 from vacuum flask, 3-seven fluorine n-propanes (≤21.4g) with ethanol (214mg).The metering valve crimping is good, with the tube sonication of filling 5 minutes.The each unlatching of this aerosol provides 250 μ g terbutaline sulfate (1%W/W ethanol).

Embodiment 14

(9.57mg) directly weighs in aluminium pot with micronized Salmeterolxinafoate, add 1 from vacuum flask, 1,1,2,3,3,3-seven fluorine n-propanes (≤21.4g) with ethanol (428mg), the metering valve crimping is good, with the tube sonication of filling 5 minutes, the each unlatching of this aerosol provided 25 μ g Salmeterolxinafoates (2%W/W ethanol).

Embodiment 15

(13.3mg) directly weighs in aluminium pot with micronized FLUTICASONE PROPIONATE, adds 1,1,1,2,3,3 from vacuum flask, 3-seven fluorine n-propanes (≤21.4g) and ethanol (107mg).The metering valve crimping is good, with the tube sonication of filling 5 minutes.The each unlatching of this aerosol provides 50 μ g FLUTICASONE PROPIONATE (0.5%W/W ethanol).

Embodiment 16

Micronized salbutamol sulfate (31.7mg) is directly weighed in aluminium pot, add 1,1,1,2,3,3 from vacuum flask, 3-seven fluorine n-propanes (≤21.4g) and ethanol (535mg).The metering valve crimping is good, with the tube sonication of filling 5 minutes.The each unlatching of this aerosol provides 100 μ g salbutamol sulfate (2.5%W/W ethanol)

Embodiment 17

(13.6mg) directly weighs in aluminium pot with micronized Beclomethasone, directly adds 1,1,1,2,3,3 from vacuum flask, 3-seven fluorine n-propanes (≤21.4g) and ethanol (107mg).The metering valve crimping is good, with the tube sonication of filling 5 minutes.The each unlatching of this aerosol provides 50 μ g Beclomethasones (0.5%W/W ethanol).

Embodiment 18

Each inhaler %W/W opens Sha Maiteluo Hydroxynaphthoate 0.048 36.25 microgram FLUTICASONE PROPIONATE 0.132 100 microgram ethanol 1.0 0.76mg1 at every turn, 1,1,2-tetrafluoroethane to 100≤75.8mg

Embodiment 19

Each inhaler %W/W opens Sha Maiteluo Hydroxynaphthoate 0.048 36.25 microgram FLUTICASONE PROPIONATE 0.330 250 microgram ethanol 2.5 1.9mg1 at every turn, 1,1,2-tetrafluoroethane to 100≤75.8mg

Embodiment 20

Each inhaler %W/W opens Salmeterolxinafoate 0.04g 36.25 microgram FLUTICASONE PROPIONATE 0.066 50 microgram ethanol 0.5 0.38mg1 at every turn, 1,1,2-tetrafluoroethane to 100≤75.8mg

Embodiment 21

Each inhaler %W/W opens Salmeterolxinafoate 0.04g 36.25 microgram FLUTICASONE PROPIONATE 0.165 125 microgram ethanol 1.0 0.76mg1 at every turn, 1,1,2-tetrafluoroethane to 100≤75.8mg

Embodiment 22

Each inhaler %W/W opens salbutamol at every turn ^*0.132 100 μ g FLUTICASONE PROPIONATE, 0.132 100 μ g ethanol, 1.0 0.76mg1,1,1,2-tetrafluoroethane to 100≤75.8mg ^*As free alkali or salt, sulfate for example, its consumption is as the concrete concentration of the medicine that provides.

Embodiment 23

Each inhaler %W/W opens salbutamol at every turn ^*0.264 200 μ g FLUTICASONE PROPIONATE, 0.330 250 μ g ethanol, 2.0 1.52mg1,1,1,2-tetrafluoroethane to 100≤75.8mg ^*As free alkali or salt, sulfate for example, its consumption is as the concrete concentration of the medicine that provides.

Embodiment 24

Each inhaler %W/W opens Salmeterolxinafoate 0.048 36.25 μ g FLUTICASONE PROPIONATE 0.066 50 μ g ethanol 0.5 0.3gmg1 at every turn, 1,1,2-tetrafluoroethane to 100≤75.8mg

Embodiment 25

Each inhaler %W/W opens Salmeterolxinafoate 0.048 36.25 μ g FLUTICASONE PROPIONATE 0.264 200 μ g ethanol 0.5 0.38mg1 at every turn, 1,1,2-tetrafluoroethane to 100≤75.8mg

Embodiment 26

Each inhaler %W/W opens salbutamol at every turn ^*0.132 100 μ g FLUTICASONE PROPIONATE, 0.066 50 μ g ethanol, 2.0 1.52mg1,1,1,2-tetrafluoroethane to 100≤75.8mg ^*As free alkali or salt, sulfate for example, its consumption is as the concrete concentration of the medicine that provides.

Embodiment 27

Each inhaler %W/W opens salbutamol at every turn ^*0.264 200 μ g FLUTICASONE PROPIONATE, 0.264 200 μ g ethanol, 2.5 1.9mg1,1,1,2-tetrafluoroethane to 100≤75.8mg ^*As free alkali or salt, sulfate for example, its consumption is as the concrete concentration of the medicine that provides.

In embodiment 18-27, micronized medicine is weighed and is packed into behind the aluminium pot, adds 1,1,1 from vacuum flask, and 2-tetrafluoroethane and ethanol are good with the metering valve crimping again.

Claims

1, a kind of medicinal aerosol formulations, it comprises granulated drug, as 1,1,1 of propellant, 2-tetrafluoroethane, 1,1,1,2,3,3,3-seven fluorine n-propanes or its mixture and be the polar co-solvent that benchmark calculates 0.01-5%w/w with the propellant, said polar co-solvent is C _2-6Aliphatic alcohol or polyhydric alcohol or its mixture, said preparation is substantially free of surfactant.

2, according to the medicinal aerosol formulations of claim 1, it is mainly by one or more granulated drug, as 1 of propellant, 1,1,2-tetrafluoroethane, 1,1,1,2,3,3, the polar co-solvent of 3-seven fluorine n-propanes or its mixture and the 0.01-5%w/w that calculates by benchmark with the propellant is formed, and said polar co-solvent is C _2-6Aliphatic alcohol or polyhydric alcohol or its mixture.

3, according to the medicinal aerosol formulations of claim 1, it is by one or more granulated drug, as 1 of propellant, 1,1,2-tetrafluoroethane, 1,1,1,2,3,3, the polar co-solvent of 3-seven fluorine n-propanes or its mixture and the 0.01-5%w/w that calculates by benchmark with the propellant is formed, and said polar co-solvent is C _2-6Aliphatic alcohol or polyhydric alcohol or its mixture.

4, according to the preparation of claim 1, wherein said medicine is anti-allergic drug, bronchodilator or anti-inflammatory type sterol compounds.

5, according to the preparation of claim 1, wherein said medicine is a bronchodilator.

6, according to the preparation of claim 1, wherein said medicine is ephedrine, epinephrine, fenoterol, formoterol, isoprenaline, alotec, phenylephrine, phenylpropanolamine, pyrrole butanols, D-1959, asmaten, terbutaline, Dilabron, C-78, hydroxyl is breathed heavily or (-)-4-amino-3,5-two chloro-α-[[[6-[2-(2-pyridine radicals) ethyoxyl] hexyl] amino] methyl] benzyl alcohol or the last acceptable salt of its physiology.

7, according to the preparation of claim 6, its Chinese medicine is the pyrrole butanols.

8, according to the preparation of claim 1, its Chinese medicine is selected from salmaterol, salbutamol, FLUTICASONE PROPIONATE, Beclomethasone and physiology thereof and goes up acceptable salt and solvate.

9, preparation according to Claim 8, its Chinese medicine are salbutamol or salmaterol or its physiologically acceptable salt.

10, preparation according to Claim 8, it contains Beclomethasone or its physiologically acceptable solvate.

11, according to the preparation of claim 1, it contains two or more granulated drug.

12, according to the preparation of claim 11, it comprises granular bronchodilator and granular antibiotic medicine.

13, according to the preparation of claim 12, it comprises salmaterol or its physiologically acceptable salt of combining with FLUTICASONE PROPIONATE.

14, according to the preparation of claim 13, it comprises the Salmeterolxinafoate of combining with FLUTICASONE PROPIONATE.

15, according to the preparation of claim 1, wherein polar co-solvent is ethanol, isopropyl alcohol or propylene glycol or its mixture.

16, according to the preparation of claim 1, wherein the consumption of polar co-solvent is that benchmark is calculated as 0.05-3%w/w with the propellant.

17, according to the preparation of claim 1, wherein the consumption of polar co-solvent is that benchmark is calculated as 0.01-1%w/w with the propellant.

18, according to the preparation of claim 1, wherein amount of drug is that benchmark is calculated as 0.01-1%w/w with the total formulation weight amount.

19, according to the preparation of claim 2, wherein said medicine is selected from salmaterol, salbutamol, FLUTICASONE PROPIONATE, Beclomethasone and physiologically acceptable salt and solvate.

20, preparation according to Claim 8, wherein polar co-solvent is ethanol, isopropyl alcohol or propylene glycol or its mixture.

21, according to the preparation of claim 20, wherein the consumption of polar co-solvent is that benchmark is calculated as 0.05-3%w/w with the propellant.

22, according to the preparation of claim 19, wherein polar co-solvent is ethanol, isopropyl alcohol or propylene glycol or its mixture.

23, according to the preparation of claim 22, wherein the consumption of polar co-solvent is that benchmark is calculated as 0.05-3%w/w with the propellant.

24, according to the preparation of claim 2, wherein polar co-solvent is ethanol, isopropyl alcohol or propylene glycol or its mixture.

25, according to the preparation of claim 2, wherein the consumption of polar co-solvent is that benchmark is calculated as 0.05-3%w/w with the propellant.

26, according to the preparation of claim 2, wherein the consumption of polar co-solvent is that benchmark is calculated as 0.01-1%w/w with the propellant.

27, according to the preparation of claim 2, wherein amount of drug is that benchmark is calculated as 0.01-1%w/w with the total formulation weight amount.

28, according to the preparation of claim 2, its Chinese medicine is that Salmeterolxinafoate and polar co-solvent are ethanol.

29, a kind of device that is suitable for discharging the medicinal aerosol formulations of claim 1-28, it comprises a container that can bear used propellant vapour pressure, this container seals with a metering valve, and each medicinal aerosol formulations is housed among the claim 1-28.

30, a kind of metered dose inhaler upon actuation that is suitable for discharging the medicinal aerosol formulations of claim 1-28, it comprises the device of the claim 29 that is installed to suitable lane device.